LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, held December 6-10 in Los Angeles. The company will showcase its therapies and technologies for drug-resistant epilepsy through several scientific posters, aiming to enhance understanding of non-pharmacological seizure treatments. Additionally, LivaNova will present in-progress data from its real-world evidence study, “CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy.”
“Accelerating access to care and enhancing the quality of life for epilepsy patients globally are key priorities for LivaNova,” said Stephanie Bolton, President of Global Epilepsy at LivaNova. “These poster presentations, featuring interim data from our CORE-VNS study as well as other clinical and health economic research, reflect our ongoing commitment to advancing epilepsy research.”
The scientific poster presentations will showcase the research of both LivaNova employees and independent investigators. Attendees of the 2024 AES Annual Meeting will have the opportunity to view the posters on Saturday, December 7, and Sunday, December 8, with author presentations from 12:00 – 2:00 p.m. PST each day. The posters will also be displayed in the LivaNova Scientific Exhibit on Monday, December 9, from 8:00 – 11:00 a.m. PST.
Abstracts and poster details are available on the American Epilepsy Society website.
Saturday, December 7
- CORE-VNS: Dosing and Titration of VNS Therapy™ in Contemporary Clinical Practice (1.515) – Presented by Ryan Verner, PhD, LivaNova PLC, Houston, Texas
- Long-Term Adjunctive VNS Therapy™ Use in Patients with Genetic Epilepsy – 24-Month CORE-VNS Outcomes (1.517) – Presented by Nicola Specchio, MD, PhD, FCCP, Rome, Italy
- Long-term Experience of VNS Therapy™ in Children <18 Years of Age – 24-Month Outcomes from the CORE-VNS Study (1.516) – Presented by Muhammad Zafar, MD, FACNS, Durham, North Carolina
- Focal Onset Seizure Response in Children 4-18 Years at 24 Months – Outcomes from the CORE-VNS Study (1.514) – Presented by James Wheless, MD, Memphis, Tennessee
- Exploratory Analysis of an fMRI-Guided Titration Paradigm for Microburst VNS Therapy™ (1.513) – Presented by Ann Mertens, MD, Gent, Belgium
- The Journey of Medicaid Enrollees with Drug-Resistant Epilepsy (DRE) to Neuromodulation (1.507) – Presented by Kathryn Evans, MPH, Bethesda, Maryland
- Comparison of Healthcare Services and Costs Over the 2-Year Periods Immediately Before and After Vagus Nerve Stimulation (VNS Therapy™) Implantation Among Medicaid Enrollees with Drug-Resistant Epilepsy (DRE) (1.508) – Presented by Bronwyn Do Rego, MS, LivaNova PLC, London, England
- Sleep Quality in Children with Confirmed Genetic Epilepsy Undergoing VNS Therapy™ (1.523) – Presented by Maxine Dibue, PhD, LivaNova PLC, London, England
Sunday, December 8
- Long-term Experience of VNS in Lennox-Gastaut Syndrome at 24 Months from the CORE-VNS Registry (2.249) – Presented by Paul D. Lyons, MD, PhD, Winchester, Virginia
- Long-Term Outcomes in Patients with Generalized Tonic-Clonic Seizures Following VNS Therapy™: Interim CORE-VNS 36 Months (2.250) – Presented by Ana Suller-Marti, MD, PhD, London, Ontario, Canada
About VNS Therapy™ for Epilepsy
VNS Therapy is a clinically proven, safe, and effective adjunctive treatment for drug-resistant epilepsy in adults and children as young as 4 years old with partial onset seizures. It is designed to help reduce seizure frequency and offers a unique treatment approach for people with drug-resistant epilepsy, which affects approximately one in three people with epilepsy. For more information, visit VNSTherapy.com.
Incidence of adverse events following stimulation (>5%) include voice alteration/hoarseness, increased coughing, sore throat, tingling or prickling of the skin, shortness of breath, and nausea. Infection is the most common complication of the surgical procedure. See important safety information at VNSTherapy.com/safety.
INTENDED USE/INDICATIONS FOR USE – UNITED STATES
The VNS Therapy™ System is indicated as an adjunctive therapy for reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.
About LivaNova
LivaNova PLC is a global medical technology company with nearly five decades of experience and a commitment to providing life-changing solutions in neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 people and operates in over 100 countries to benefit patients, healthcare professionals, and healthcare systems worldwide.
